Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04832971 · ClinicalTrials.gov registry record · Phase 2

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

A Phase 2 study of Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
204
Enrollment target
20
Study locations

NCT04832971 is a Phase 2 study of Mixed Dyslipidemia that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 204 participants, below the 671-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04832971, a Phase 2 study of Mixed Dyslipidemia, has completed, sponsored by Arrowhead Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
204 participants
Enrollment target
20
Study locations

Study Summary

The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.

Conditions Studied

Mixed Dyslipidemia

Interventions

  • DRUG Placebo
  • DRUG ARO-ANG3

Study Locations (20)

Florida

  • Research Site 7 - Hialeah
  • Research Site 17 - Miami
  • Research Site 8 - Port Orange

Other

  • Research Site 18 - Nedlands
  • Research Site 12 - Québec
  • Research Site 9 - Québec

North Carolina

  • Research Site 15 - Greensboro
  • Research Site 2 - Morehead City

California

  • Research Site 5 - Huntington Park

Minnesota

  • Research Site 24 - Minneapolis

Nebraska

  • Research Site 10 - Omaha

Nevada

  • Research Site 23 - Las Vegas

New York

  • Research Site 22 - New York

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2021-06-28
Est. Completion 2024-09-25
Phase Phase 2

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04832971

The ClinicalTrials.gov registry entry for NCT04832971 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 671-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (70% lower). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mixed Dyslipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04832971 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Other, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04832971 about?

NCT04832971 is a clinical study titled "Study of ARO-ANG3 in Adults With Mixed Dyslipidemia". The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-lab...

What is the current status of trial NCT04832971?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2021-06-28. Estimated completion is 2024-09-25.

What conditions does trial NCT04832971 study?

This clinical trial studies the following conditions: Mixed Dyslipidemia.

What interventions are being tested in trial NCT04832971?

The interventions under investigation include: Placebo (DRUG), ARO-ANG3 (DRUG).

Who is sponsoring clinical trial NCT04832971?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04832971 being conducted?

This trial has 20 study locations across California, Florida, Minnesota, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mixed Dyslipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mixed Dyslipidemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.